How is the introduction of a new medicine regulated in the UK?
|
|
- Camron Walton
- 5 years ago
- Views:
Transcription
1 Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) A medicine called Raxone, which is produced by Santhera Pharmaceuticals and is also known as idebenone, is to be made available in the UK through the Early Access to Medicines Scheme (EAMS). Raxone has been given a positive scientific opinion by the Medicines and Healthcare Regulatory Agency (MHRA) for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids. As a result, Raxone is now available in the UK before a European marketing authorisation is granted. The manufacturer has separately applied to the European Medicines Agency (EMA) for a marketing authorisation in Europe (also known as a licence ), including the UK, and this is going through the process of review at present. Before giving an EAMS positive opinion the MHRA reviewed information supplied by the manufacturer and determined that Raxone is considered overall to have an acceptable safety profile, based on the information provided, and was satisfied that the company is able to supply the medicine according to a consistent quality standard. In conclusion, considering the very high level of unmet need in this patient population, and that the benefits outweigh the risks, early access to Raxone for DMD patients as defined in the scope of the EAMS indication is considered to be justified. This medicine will not be suitable for everybody and people with DMD need to discuss their own condition with a specialist doctor who knows them and what has been happening to them. Details of the EAMS assessment are available in the Public Assessment Report at ne_final_public_assessment_report.pdf
2 FAQs How is the introduction of a new medicine regulated in the UK? A prescription medicine that is proposed to be used in a new medical condition must be licensed for that use in the countries of the European Union by the European Medicines Agency. The Committee on Human Medicinal Products (CHMP) makes a thorough review of detailed information provided by the manufacturer of the medicine and will recommend if a product should receive a Marketing Authorisation (also known as a product licence ) in the European Union. The information includes the results of clinical trials that have been completed using the medicine in people with the condition that is being studied. What is the Early Access to Medicines Scheme? The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising medicines, before the normal European product licensing process is completed, to patients in the UK where there is high unmet clinical need. The medicinal products included in the scheme are those that are intended to treat, diagnose or prevent seriously debilitating or life threatening conditions where there are no adequate treatment options. The scheme is regulated by the Medicines and Healthcare Regulatory Agency (MHRA) in the UK. More information about the scheme can be found on its website here: dex.htm The MHRA scientific opinion provides benefit and risk information to doctors who may wish to prescribe the unlicensed medicine under their own responsibility. The EAMS programme is only open to include new people until a product gets a European product licence, then no new people can be added to the scheme. What is Raxone? Raxone is a medicine that contains a substance called idebenone in tablet form. Idebenone is a potent anti-oxidant and is believed to improve the functioning of mitochondria (important for the generation of cellular energy) inside cells. Who will be able to have this treatment in the scheme? Raxone will only be available with a prescription from a specialist doctor with experience in managing people with DMD. A specialist doctor can advise on whether the scheme might be suitable for an individual person. Raxone has received positive opinion for use within the EAMS programme to slow the rate
3 of decline of breathing ability in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are not taking glucocorticoids (also known as steroids ). This is because clinical trials have only been completed with this medicine in patients of this age with DMD who were not taking steroids. Breathing ability is usually measured by lung function tests, and typically these show that function begins to decline in people with DMD around the time they lose ambulation and require a wheelchair most of the time. Lung function decline must be confirmed by spirometry (which measures the maximum flow and amount of air that can be exhaled in one breath) before Raxone is given. Raxone is given without glucocorticoids and can only be given to patients previously treated with glucocorticoids, such as prednisolone or deflazacort, or in patients who are not candidates for continuation or commencement of glucocorticoid treatment. Importantly, Raxone is not a replacement for steroids and people with DMD should not decide to stop steroids solely so that they can start Raxone. A specialist doctor with experience of managing people with DMD can advise on the benefits of continuing steroid therapy for an individual person. Is this medicine used to treat other conditions? Raxone already has a European product licence for treatment of an inherited mitochondrial eye disease, Leber s Hereditary Optic Neuropathy (LHON). The patient information leaflet for this condition can be found here: How does the EAMS work? The EAMS allows medicines to be prescribed by UK specialist doctors to treat people before it has a European product licence. This is not a clinical trial; it is more like how the medicine will be used in real life once it has a licence. However extra care will be taken as this is a new medicine in DMD. Treatment will only be provided in specialist centres who are experienced in managing DMD and there is the requirement for certain monitoring to ensure the safety of patients during the EAMS. People with DMD may discuss together with their doctor whether they are suitable for this treatment and a joint decision would be made whether they want to go ahead. They would be asked to sign a consent form once they have considered all the information. The company that makes Raxone will provide the medicine to the NHS free of charge during EAMS.
4 Where will the treatment be available? This scheme is only available to the National Health Service in England, Scotland, Ireland and Wales. Raxone will only be available through EAMS on prescription through specialist centres which are experienced in treating DMD. The MHRA scientific opinion provides benefit and risk information to doctors who may wish to prescribe the unlicensed medicine under their own responsibility. When will the treatment be available? The MHRA has given Raxone a positive scientific opinion allowing access to Raxone through EAMS and specialist centres in the NHS should be able to implement the scheme across the UK within a short time. Because of the ongoing European regulatory review the EAMS programme will likely be open to include new people for a few months, as once Raxone gets a European licence then no new people can be added to the EAMS scheme. Who can advise someone with DMD about eligibility for the scheme? The first step is for a person with DMD to discuss it with their specialist doctor. What does the treatment involve? Raxone comes as tablets which need to be taken three times a day with food. If someone has difficulty in swallowing, tablets can, if necessary, be crushed into semi-solid food, or into liquid feed for administration through a tube into the stomach. What are the possible side effects? Like all medicines, Raxone can cause side effects, although not everyone gets them. The MHRA and the Company will make available a leaflet written for people with DMD that explains more about Raxone and its effects. Specialist doctors will also be able to explain this further. A risk management plan has been developed to ensure that Raxone is used as safely as possible. Are there extra tests and hospital visits required? In most circumstances no extra tests are required for participants in the scheme beyond what is routine practice. Doctors will want to keep in touch regularly with their patients to know how they are finding the new treatment. In particular they will want to know about any side effects they experience.
5 Who pays for the treatment during EAMS? During EAMS the medicine is provided free-of-charge to the NHS by the company who makes it. The NHS pays for other aspects of clinical care, such as tests and clinic appointments, just as they do at present. The NHS will begin to pay for the medicine after EAMS has closed and once NHS funding has been agreed in each country of the UK. What happens if/when the medicine gets a licence in Europe? The scientific opinion is based on the information supplied to the MHRA on the benefits and risks of a promising new medicine. As such this is a scientific opinion and should not be regarded as a medicine licensed by the MHRA or a future commitment by the MHRA to licence such a medicine. An EAMS scheme has to close to new patients if/when the medicine receives a licence from the EMA. People who are already enrolled in the scheme may continue taking the medicine provided free of charge by the manufacturer for as long as their doctor considers it to be beneficial until the NHS has made decisions about funding. Santhera Pharmaceuticals intends to make Raxone available through EAMS free of charge to local NHS services for a minimum of one year for each individual patient, if recommended by a doctor s prescription. Santhera may extend this period at its discretion, or shorten it if the NHS agrees to fund Raxone sooner, or if important new information emerges. How and when is NHS funding of a new medicine decided? These decisions are made by different organisations in the different countries of the UK according to their own evaluation processes: England (National Institute for Health and Care Excellence (NICE) and NHS England), Wales (NICE or All Wales Medicines Strategy Group (AWMSG) and NHS Wales), Scotland (Scottish Medicines Consortium (SMC) and NHS Scotland) and Northern Ireland (NICE and NHS Northern Ireland). It is not possible to predict if the NHS will fund a newly-licensed medicine in each country or when these funding decisions may be made. The evaluation processes usually involve clinical specialists and representatives from patient charities as well as the manufacturer of the medicine, and they may take many months to complete. 1-L V1-1 Date of preparation: June 2017
Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone
Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) April 26 th 2018 Raxone tablets
More informationUSE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE
NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus
More informationAdvancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationUse of unlicensed medicines and off-label uses
Use of unlicensed medicines and off-label uses 25 Promoting hope and wellbeing together What is this leaflet about? Your doctor or pharmacist has given you this leaflet because a medicine that you have
More informationSanthera Pharmaceuticals Company Presentation. September 2018
Santhera Pharmaceuticals Company Presentation September 2018 Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationHow Clinical Trials Work
A Guide to: How Clinical Trials Work Clinical trials are rigorously controlled tests designed to examine the safety and / or effectiveness of medicines, devices, treatments, or preventive measures in humans.
More informationSummary of the risk management plan (RMP) for Raxone (idebenone)
EMA/467186/2015 Summary of the risk management plan (RMP) for Raxone (idebenone) This is a summary of the risk management plan (RMP) for Raxone, which details the measures to be taken in order to ensure
More informationA Guide to the Scottish Medicines Consortium
A Guide to the Scottish Medicines Consortium Providing advice about newly licensed medicines www.scottishmedicines.org About the Scottish Medicines Consortium The Scottish Medicines Consortium (SMC) provides
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationSWISS BIOTECH DAY 2018
SWISS BIOTECH DAY 2018 Basel, 3 May 2018 Thomas Meier, CEO Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationPackage leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone
Package leaflet: Information for the user Raxone 150 mg film-coated tablets idebenone This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationE096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability
E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,
More informationRaxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD)
Raxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Thomas Meier, PhD February 2018 Agenda Medical need for effective treatment of respiratory illness in DMD Understanding respiratory
More informationIdebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals,
Idebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals, Inc Disclaimer This presentation is not and under no circumstances
More informationFrequently asked questions
13 February 2017 EMA/527628/2011 Rev. 1 Directorate This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question
More informationChronic conditions explained
Chronic conditions explained The limits of your cover for treatment of chronic medical conditions April 2015 Contents Undertanding chronic conditions Why it s important for you to understand 3 about chronic
More informationResponse to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014
Responseto ScottishGovernment AConsultationonElectronicCigarettesand StrengtheningTobaccoControlinScotland December2014 Contact Janice Oman Scotland Representation Manager National Pharmacy Association
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationWyss Zürich Regulatory Affairs Seminar
Wyss Zürich Regulatory Affairs Seminar Hospital Exemption & Compassionate Use EU Framework Catherine Longeval Koen T Syen Zürich, 5 July 2017 1 Table of contents Introduction Hospital Exemption Implementation
More information58. Translarna drug Policy for use. The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care:
58. Translarna drug Policy for use The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care: What his policy is regarding the use of the drug Translarna? The President:
More informationTreating Barrett s oesophagus with photodynamic therapy
Understanding NICE guidance Information for people who use NHS services Treating Barrett s oesophagus with photodynamic therapy NICE interventional procedures guidance advises the NHS on when and how new
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationA guide to essential gluten-free foods available from the pharmacy
A guide to essential gluten-free foods available from the pharmacy This information guide has been produced by For further information: This resource has been reviewed by the British Dietetic Association.
More informationTreating severe obesity using keyhole surgery to stitch folds in the stomach to make it smaller
Issue date November 2012 Information for the public NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical practice. Treating severe obesity using
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationConsent to research. A draft for consultation
Consent to research A draft for consultation 1 Consent to research About the guidance Our guidance Consent: patients and doctors making decisions together (2008) 1 sets out the principles of good practice
More informationInformation about... Uveitis. Ophthalmology Service Scottish Uveitis National Managed Clinical Network
Information about... Uveitis Ophthalmology Service Scottish Uveitis National Managed Clinical Network The information in this leaflet is intended to help you to understand what uveitis is, what the treatment
More informationSpecialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT
Specialist Research Ethics Guidance Paper RESEARCH INVOLVING ADULT PARTICIPANTS WHO LACK THE CAPACITY TO CONSENT This note covers all research undertaken at the University that involves the recruitment
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationStaying steady. Health & wellbeing. Improving your strength and balance. AgeUKIG14
Staying steady Improving your strength and balance Health & wellbeing AgeUKIG14 Age UK is the new force combining Age Concern and Help the Aged. With almost 120 years of combined history to draw on, we
More informationSanthera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone
Santhera will hold a webcast tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST. Details at the end of statement. Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive
More informationIncisionless surgery to correct protruding ears
Issue date March 2012 Understanding NICE guidance Information for people who use NHS services Incisionless surgery to correct protruding ears NICE interventional procedures guidance advises the NHS on
More informationTransplanting donated pancreatic islet cells for patients with type 1 diabetes
Understanding NICE guidance Information for people who use NHS services Transplanting donated pancreatic islet cells for patients with type 1 diabetes NICE interventional procedures guidance advises the
More informationGuideline scope Smoking cessation interventions and services
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Smoking cessation interventions and services This guideline
More informationSmile. Your dental team have check ups too
Smile Your dental team have check ups too Whether you re visiting for a routine check up, a quick clean or for more involved treatment, the dental professional treating you (and their services) must meet
More informationProcess for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015
Introduction Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015 From September 2015 the All Wales Medicines Strategy
More informationTreating atrial fibrillation using heat energy delivered to the outside of the heart through a thin tube
Issue date March 2009 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationFlash Glucose Monitoring (Flash GM) Frequently asked questions (November 2018)
Flash Glucose Monitoring (Flash GM) Frequently asked questions (November 2018) What is Flash Glucose Monitoring (Flash GM)? Flash glucose monitoring is a small sensor that you wear on your skin (usually
More informationUnproven treatments and motor neurone disease
C Unproven treatments and motor neurone disease This information sheet presents the facts about alternative or unproven treatments. It aims to provide people with the information they need in order to
More informationTreating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate
Issue date April 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationInformation for Patients. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Information for Patients Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction October 2002 What is NICE Guidance? The National Institute for Clinical Excellence
More informationAbiraterone: Reaching men who need it the most
Abiraterone: Reaching men who need it the most Abiraterone a new, life extending drug for incurable prostate cancer has been making headlines for all the wrong reasons. The National Institute for Health
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?...................3 About the swine flu vaccine...........4 What else do I need to know?.........8
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
About you Your name: xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Name of your organisation: The Prostate Cancer Charity Are you (tick all that apply): an employee of a patient organisation that represents
More informationLidocaine adult mouthwash 2mg in 1ml. Information for patients Pharmacy
Lidocaine adult mouthwash 2mg in 1ml Information for patients Pharmacy This leaflet contains important information about your medicine, please read it carefully. If you have any questions, contact your
More informationwhat you need flu. Protect yourself and others.
swine flu vaccination: what you need to know flu. Protect yourself and others. contents What is swine flu?................ 3 About the swine flu vaccine........ 4 What else do I need to know?....... 8
More informationNHS GG&C Introduction of Freestyle Libre flash glucose monitoring system
NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid
More informationPutting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)
Putting NICE guidance into practice Resource impact report: Hearing loss in adults: assessment and management (NG98) Published: June 2018 Summary This report focuses on the recommendation from NICE s guideline
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationMEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH
11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
More informationLidocaine Hydrochloride BP 2% w/v in Lutrol F127 24% w/v Sterile Gel. Information for patients Pharmacy
Lidocaine Hydrochloride BP 2% w/v in Lutrol F127 24% w/v Sterile Gel Information for patients Pharmacy This leaflet contains important information about your medicine; please read it carefully. If you
More informationKey to Survival - Unlocking access to new treatments
Key to Survival - Unlocking access to new treatments Our new Key to Survival campaign sets out to achieve nothing less than a step change. We want to make sure all pancreatic cancer patients can access
More informationChanging practice to support service delivery
Nurse and Midwife Medicinal Product Prescribing Toolkit Authorised Medicinal Products, Off-label Prescription and Exempt Medicinal Products Toolkit Changing practice to support service delivery Introduction
More informationNEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting
The Pharmacovigilance Risk Assessment Committee (PRAC) Meeting 7-10 July 2014 Finalised safety procedure for methadone products containing povidone Only high molecular weight povidone was associated with
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA 118 Colorectal cancer (metastatic) - bevacizumab &
More informationDear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE
Directorate of Chief Medical Officer T: 0131-244 2470 E: John.Hannah@gov.scot Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE Following my letter of 31 October 2018
More informationNorthumbria Healthcare NHS Foundation Trust. Bronchiectasis. Issued by Respiratory Medicine
Northumbria Healthcare NHS Foundation Trust Bronchiectasis Issued by Respiratory Medicine The aim of this booklet is to help you manage your bronchiectasis. It contains information which you should find
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA96; Adefovir dipivoxil and peginterferon alfa-2a for
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationNHS. Living-donor lung transplantation for end-stage lung disease. National Institute for Health and Clinical Excellence. Issue date: May 2006
NHS National Institute for Health and Clinical Excellence Issue date: May 2006 Living-donor lung transplantation for end-stage Understanding NICE guidance information for people considering the procedure,
More informationA combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.
PHA Position Statement E-cigarettes 30 May 2014 The Public Health Agency (PHA) considers E-cigarettes with caution at this time. E-cigarettes are not licensed nicotine replacement products. They are not
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA215; Pazopanib for the first line treatment of advanced
More informationGood Practice Guidance on Covert Administration of Medication
Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their
More informationUsing selective internal radiation therapy to treat bowel cancer that has spread to the liver
Understanding NICE guidance Information for people who use NHS services Using selective internal radiation therapy to treat bowel cancer that has spread to the liver NICE interventional procedures guidance
More informationDRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.
Enclosure No: Agenda item No: Author: Contact: xx/xxxxx/xxxx0918 xx CEPP National Audit: Antipsychotics in Dementia All Wales Therapeutics and Toxicology Centre Tel: 02920 71 6900 awttc@wales.nhs.uk 1.0
More informationRadon Guidance for Local Authorities
Radon Guidance for Local Authorities Description and Background Radon is an odourless, colourless, radioactive gas that occurs naturally. It is released from certain rocks and the risk of occurrence varies
More informationTechnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499
Glecaprevir pibrentasvir for treating chronic hepatitis C Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499 NICE 2018. All rights reserved. Subject to Notice of rights
More informationProcess for End of Life and Very Rare Conditions (orphan and ultra-orphan medicines)
PACE (Patient & Clinician Engagement) Overview Document Process for End of Life and Very Rare Conditions (orphan and ultra-orphan medicines) Introduction The Scottish Medicines Consortium (SMC) has changed
More informationImplanting pressure monitors in the pulmonary artery to monitor chronic heart failure
Issue date August 2013 Information for the public Implanting pressure monitors in the pulmonary artery to monitor chronic heart failure NICE interventional procedures guidance advises the NHS on when and
More informationWhat happens if I cannot make decisions about my care and treatment?
Information Line: 0800 999 2434 Website: compassionindying.org.uk What happens if I cannot make decisions about my care and treatment? This factsheet explains how decisions are made about your care or
More informationSCOTTISH PARLIAMENTARY EVENT 12 TH NOVEMBER 2014
SCOTTISH PARLIAMENTARY EVENT 12 TH NOVEMBER 2014 INTRODUCTION The Specialised Healthcare Alliance (SHCA) is a coalition of over 100 patient-related organisations, supported by 14 corporate members, which
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationUNDERSTANDING GP ATTITUDES TO CANCER PREVENTING DRUGS FEBRUARY 2017
UNDERSTANDING GP ATTITUDES TO CANCER PREVENTING DRUGS FEBRUARY 2017 EXECUTIVE SUMMARY Around four in 10 cases of cancer could be prevented in the UK, largely through lifestyle changes. In addition, chemoprevention
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationLow back pain and sciatica in over 16s NICE quality standard
March 2017 Low back pain and sciatica in over 16s NICE quality standard Draft for consultation This quality standard covers the assessment and management of non-specific low back pain and sciatica in young
More informationSCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE
SCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE 02 Changes in our lives can be stressful and leaving school and moving into the
More informationFoker technique for long-gap oesophageal atresia
Issue date: January 2006 Foker technique for long-gap oesophageal atresia Understanding NICE guidance information for parents and carers considering the procedure, and for the public Information about
More informationSpanish routes for making available medicines to patients before authorisation
Spanish routes for making available medicines to patients before authorisation César Hernández García Head of Department of Medicines for Human Use Spanish Agency of Medicines and Medical Devices (AEMPS)
More informationAbdominal aortic aneurysm. Information for patients Sheffield Vascular Institute
Abdominal aortic aneurysm Information for patients Sheffield Vascular Institute page 2 of 12 You have been diagnosed as having an abdominal aortic aneurysm. This leaflet explains more about abdominal aortic
More informationTechnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507
Sofosbuvir velpatasvir voxilaprevir for treating chronic hepatitis C Technology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 NICE 2018. All rights reserved. Subject to Notice
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationFacilitating adoption of off-patent, repurposed medicines into NHS clinical practice
Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice December 2017 Contents FOREWORD... 4 1. EXECUTIVE SUMMARY... 6 2. INTRODUCTION... 9 3. BACKGROUND... 12 4. LICENSING...
More informationLegal. Advance Directives. About this factsheet. Factsheet Leg 8 October of 12
Legal Advance Directives About this factsheet Factsheet Leg 8 October 2016 1 of 12 This factsheet provides information on how you can clearly set out your wishes for your health care, particularly if you
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationOnline Form. Welcome to the Integrated Research Application System. IRAS Project Filter
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationDIRECT ACCESS - Guidance to BSDHT Members
DIRECT CCESS - Guidance to BSDHT Members Direct ccess came into effect from 1 May 2013. But what does it mean for dental hygienists and dental therapists? The GDC have published guidance notes on the subject
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationKeyhole surgery to flush out the knee joint and remove damaged tissue to treat osteoarthritis
Issue date August 2007 Understanding NICE guidance Information for people who use NHS services Keyhole surgery to flush out the knee joint and remove damaged tissue to treat osteoarthritis NICE interventional
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationReview of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy
Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines
More informationClinical Trials in Psoriasis
Clinical Trials in Psoriasis A positive approach to psoriasis and psoriatic arthritis Introduction When you go to the pharmacy to collect the treatment your doctor has prescribed, have you ever wondered
More informationTranslating Science. Transforming Lives. ACT DMD Clinical Trial Results
Translating Science. Transforming Lives ACT DMD Clinical Trial Results FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationThe prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics
Tablet Press EXTRA The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics March 2017 Use of Buccolam (buccal midazolam) for breakthrough
More informationMedical Devices - Reporting to MHRA.. Emma Rooke, December 2015
Medical Devices - Reporting to MHRA. Emma Rooke, December 2015 Topics to be covered today: The MHRA and what we do What is a Medical Device? Adverse Incidents Reporting adverse incidents to the MHRA The
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More information